Tag: Al Aziziya

Determining Whether to Submit an ANDA or a 505(b)(2) Application in USFDA Part II SUBMISSION THROUGH THE APPROPRIATE ABBREVIATED APPROVAL PATHWAY A. Regulatory Considerations for ANDAs and 505(b)(2) Applications 1. Duplicates FDA generally will refuse to file a 505(b)(2) application for a drug that is a duplicate of a listed drug and eligible for approval…

Read More “Determining Whether to Submit an ANDA or a 505(b)(2) Application in USFDA Part II” »

Determining Whether to Submit an ANDA or a 505(b)(2) Application in USFDA This guidance is intended to serve as a foundational guidance to assist applicants in determining which one of the abbreviated approval pathways under the Federal Food, Drug, and Cosmetic Act (FD&C Act) is appropriate for the submission of a marketing application to FDA…

Read More “Determining Whether to Submit an ANDA or a 505(b)(2) Application in USFDA” »

Current Trends in Cleaning Validation Rings on Buffer and Media Tanks Health based limits FDA Trends Process Understanding Trend 1: Rings in Buffer tanks Initial Incident Discovery   Background • Cleaning processes are designed based on – nature of the soil – condition of the soil – surface material – cleaning factors • ALI rings…

Read More “Current Trends in Cleaning Validation” »

Steps in Managing the Pharma Audit Introduction To achieve its’ objective efficiently and cost-effectively an audit should be thoroughly planned, carefully structured, systematically performed, faithfully reported, and remedial actions progressed to a timely and satisfactory conclusion. As with most issues involving people, clear and effective communication with the relevant stakeholders is essential if business benefits are to be maximised…

Read More “Steps in Managing the Pharma Audit” »

Technical Report Series (TRS) Biologicals Chronological listing 68th report: TRS 1011: 2017 67th report: TRS 1004: 2016 66th report: TRS 999: 2015 pdf, 1.31Mb 65th report: TRS 993: 2014 64th report: TRS 987: 2013 63rd report: TRS 980: 2012 pdf, 2.22Mb 62nd report: TRS 979: 2011 pdf, 3.23Mb 61st report: TRS 978: 2010 pdf, 3.70Mb 60th…

Read More “Technical Report Series (TRS) Biologicals” »

Computerised systems – EU GMP Annex 11 1. Appropriate controls for electronic documents such as templates should be implemented. Are there any specific requirements for templates of spreadsheets? H+V February 2011 Templates of spreadsheets help to avoid erroneous calculations from data remaining from previous calculations. They should be suitably checked for accuracy and reliability (annex 11 p7.1)….

Read More “Computerised systems – EU GMP Annex 11” »

Sampling of starting and packaging materials: Glycerol as per EU GMP EU GMP guide annexes: Supplementary requirements: Annex 8: Sampling of starting and packaging materials: Glycerol 1. What is the background regarding international incidents of glycerol contamination? H+V December 2007 There is a history of sporadic reports from around the world of supplies of glycerol contaminated with diethylene glycol…

Read More “Sampling of starting and packaging materials: Glycerol as per EU GMP” »

Question and Answers on WHO GMP Why is GMP important? Poor quality medicines are not only a health hazard, but a waste of money for both governments and individual consumers. Poor quality medicines can damage health A poor quality medicine may contain toxic substances that have been unintentionally added. A medicine that contains little or…

Read More “Question and Answers on WHO GMP” »

Risk-based approach as per EU Good Manufacturing Practice specific to Advanced Therapy Medicinal Products Introduction ATMPs are complex products and risks may differ according to the type of product,nature/characteristics of the starting materials and level of complexity of the manufacturing process. It is also acknowledged that the finished product may entail some degree of variability due to…

Read More “Risk-based approach as per EU Good Manufacturing Practice specific to Advanced Therapy Medicinal Products” »

Pharmacovigilance Pharmacovigilance: Pharmacovigilance WHO defines pharmacovigilance as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects of marketed medicines or those under trial. The drug regulatory agencies have the responsibility of having a well-established pharmacovigilance system to monitor adverse reactions of drugs, during the drug development phase and later…

Read More “Pharmacovigilance” »

EU and US GMP/GDP: Similarities and Differences   Reference: McGee Pharma International-Nov. 2016   Thank you for visit and for more pharma updates click here – https://pharmaguidances.com